La vendita allo scoperto per Red Canyon Resources dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Red Canyon Resources. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Red Canyon Resources (OTC:REDRF) Azioni, Report sulle vendite allo scoperto

Red Canyon Resources Ltd is a mineral resource company principally engaged in the acquisition and exploration of mineral property assets in Canada and the United States. Its projects are BC projects including Peak, Kendal, Ping, SP, and Cooper; and the United States projects including Scraper Springs and Keg. It has two geographic segments Canada and the USA. It generates the majority of its revenue from Canada.

RED CANYON RES LTD by Red Canyon Resources Ltd.

Red Canyon Resources Ltd

Financial Guidance
The following guidance is based on current market conditions and expectations and the information available to the Company today. For 2025 Talkspace continues to expect:
<ul>
<li>Revenue to be in the range of $220 million to $235 million</li>
<li>Adjusted EBITDA to be in the range of $14 million to $20 million</li>
</ul>

News

Guidance

TALK

Talkspace Affirms FY2025 Sales Guidance of $220.00M-$235.00M vs $226.60M Est

WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) reported quarterly earnings of $0.20 per share which missed the analyst consensus estimate of $0.34 by 41.18 percent. This is a 45.95 percent decrease over earnings of $0.37 per share from the same period last year. The company reported quarterly sales of $663.00 million which missed the analyst consensus estimate of $679.49 million by 2.43 percent. This is a 6.22 percent decrease over sales of $707.00 million the same period last year.

Earnings

Earnings Misses

WK Kellogg Q1 EPS $0.20 Misses $0.34 Estimate, Sales $663.00M Miss $679.49M Estimate

Business Outlook and Financial Guidance
"The first quarter book-to-bill ratio was solidly above one and we entered the second quarter with a strong outlook given the bookings momentum. While recent tariffs have caused uncertainty related to the timing of shipments and some increased costs in the near term, we are able to take advantage of our global manufacturing footprint and supply chain to mitigate their impact while continuing to invest in the future growth of our business," concluded Dr. Gitin.
For the second quarter of 2025, IPG expects revenue of $210 million to $240 million Our revenue guidance is approximately $15 million lower than it would have been due to potential shipment delays related to tariffs. These are not order cancellations and the Company expects to fulfill these orders as it optimizes production across its global footprint. The Company expects second quarter adjusted gross margin to be between 36% and 38%, including 150 to 200 basis points of impact from tariffs, and operating expenses of $86 million to $88 million. IPG anticipates delivering adjusted earnings per diluted share in the range of -$0.05 to $0.25 and adjusted EBITDA in the range of $16 million to $31 million.

IPGP

IPG Photonics Q2 Outlook: Adj EPS $(0.05)-$0.25 vs $0.31 Est; Sales $210.000M-$240.000M vs $242.19M Est

Buybacks

HESM

Hess Midstream LP Signs Accretive $200M Repurchase From Sponsors And Public

Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.01) by 200 percent. This is a 150 percent increase over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $38.90 million which beat the analyst consensus estimate of $37.42 million by 3.97 percent. This is a 12.21 percent increase over sales of $34.67 million the same period last year.

Earnings Beats

HRTX

Heron Therapeutics Q1 EPS $0.01 Beats $(0.01) Estimate, Sales $38.90M Beat $37.42M Estimate

J&amp;J Snack Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JJSF#NASDAQ">JJSF</a>) reported quarterly earnings of $0.35 per share which missed the analyst consensus estimate of $0.72 by 51.39 percent. This is a 58.33 percent decrease over earnings of $0.84 per share from the same period last year. The company reported quarterly sales of $356.10 million which missed the analyst consensus estimate of $367.04 million by 2.98 percent. This is a 1.01 percent decrease over sales of $359.73 million the same period last year.

JJSF

J&J Snack Foods Q2 Adj. EPS $0.35 Misses $0.72 Estimate, Sales $356.10M Miss $367.04M Estimate

Talkspace Q1 2025 Sales $52.18M Miss $53.31M Estimate

Portillos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTLO#NASDAQ">PTLO</a>) reported quarterly earnings of $0.05 per share which met the analyst consensus estimate. This is a 37.5 percent decrease over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $176.44 million which missed the analyst consensus estimate of $180.40 million by 2.20 percent. This is a 6.40 percent increase over sales of $165.83 million the same period last year.

PTLO

Portillos Q1 EPS $0.05, Inline, Sales $176.44M Miss $180.40M Estimate

Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.25) by 8 percent. This is a 8 percent decrease over losses of $(0.25) per share from the same period last year.

NVCT

Nuvectis Pharma Q1 EPS $(0.27) Misses $(0.25) Estimate

Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced new data from its ongoing Phase 1 study of its gene therapy candidate PCRX-201 (enekinragene inzadenovec). The <a href="https://www.globenewswire.com/Tracker?data=sPdlu4TKNZIsHxJEPTmy6FyLva5Ge3rx5UPKl7XVfE1YRsdxrAIFmq309CL0nLPgSv5WPaX_spBjEwC4uQ0KrXWNYhbirikskfe1qcEqzwA1spXxBsqKL5KGOb_P-6tAG9llQx0-2dMk6HuG_sP9Mg==">data</a> is being presented at the 2025 European Alliance of Associations for Rheumatology (EULAR) Annual Congress, taking place from June 11-14, in Barcelona, Spain.
Presentation Title: A Single Intra-articular Injection of the Gene Therapy PCRX-201 Was Safe and Provided Sustained Clinical Benefits for Patients With Moderate-to-Severe Knee Osteoarthritis Through 3 Years
Presented By:&nbsp;Philip G. Conaghan, MB BS, PhD, FRACP, FRCP, Professor of Musculoskeletal Medicine, University of Leeds, UK; Director, NIHR Leeds Biomedical Research Centre
Date &amp; Time:&nbsp;Wednesday, June 11 from 3:30 pm – 4:30 pm CEST
About PCRX-201 (enekinragene inzadenovec)
PCRX-201 (enekinragene inzadenovec) features an innovative design based on the company's proprietary high-capacity adenovirus vector platform. It is currently being studied in the fundamental, underlying chronic inflammatory processes that contribute to "wear and tear" over time in osteoarthritis of the knee, a condition that affects more than 14 million individuals in the U.S. today.
In November 2024, Pacira reported promising data from a large Phase 1 study in which PCRX-201 provided sustained improvements in knee pain, stiffness, and function through two years following local administration, with a well-tolerated safety profile. PCRX-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration and Advanced Therapy Medicinal Products (ATMP) designation from the European Medicines Agency. PCRX-201 is the first gene therapy to achieve these clinical results and earn these regulatory designations in osteoarthritis of the knee – a testament to its promise and potential.
Given the promising Phase 1 results, dosing is underway in a <a href="https://www.globenewswire.com/Tracker?data=c5NTS41A9eCJ7pBJDDcVdJl24zDQ5oUQhkXsBarkSENehjkVqxb0mhTlMeR5u4B7txnhAtd41I7RLfCjuDRiXFhwWkEBcDMKQHyg8vlFrIwBmchK9b3nYcwRh1gXCofoiDNQMJEIg-iG8nJw9v___I0HqteHZCvRV6-8wlVVtXa7_cI3BW3Z5F5OoIk_nnTui40yJ0FtHb2t5a5UtEGUCA==">Phase 2</a> study of PCRX-201 (<a href="https://www.globenewswire.com/Tracker?data=D7wLILMMFqdRJlncOrA56lLJsP-QFY5_wdKYIc0-vFYnSmm7GREJ9AszWQrwKWsaS5a4ofVFOHFPsbSZ8A4vlIjs4Lp2YB5KIg7oToeMTAoKdgzvR2muxJugdGtfhrXD_pzvzD_2Wtmdk_DRSzZfAQ==">the ASCEND study</a>) for the treatment of knee osteoarthritis. To learn more about PCRX-201 and the company's <a href="https://www.globenewswire.com/Tracker?data=DRcDeFIJ6lfhc-n94dMXJV9ZiqcHotiJw1VqdV1Csb3Nc1uPEkfNLWcfH_LupAU2OV7bdqpyZOQ7z5aWzAwYOi4AkEacArJ_0iQ9nrmknA8PmRXm_KnSRN_gmzDzuSjde1kjylIKxDK8cmlBkVvnCRftWCyl141-C6uywhgTdT4iyQgLzhDbX9ozD6e7PpYlrx9vzdOzKtei275ETd12wA==">clinical development program</a>, please visit the <a href="https://www.globenewswire.com/Tracker?data=qS5LfB_Ae7WfmI8YxuxgI8hoWWUGsoIFRbve7Blmz5ZVzc4MG-BOQjBmk4NWlB1YP0eQF0m6UDkgPuLGO6rg6FW9KDGNsZIU8ae0PMEjRSA=">investor events</a> section of the company's investor website.

Biotech

General

PCRX

Pacira BioSciences Announces It Will Present 3-Year Safety And Efficacy Data of PCRX-201 Following Single Intra-Articular Injection For Moderate-to-Severe Knee Osteoarthritis At 2025 European Alliance Of Associations For Rheumatology June 11-14 2025 In Barcelona, Spain

<ul>
<li>400V high-voltage coolant heater (HVCH) technology to be used in series of plug-in hybrid electric vehicles</li>
<li>HVCH offers flexible and compact design with high thermal power density
<ul>
<li>Marks the company's largest&nbsp;eHeater contract for plug-in hybrid electric vehicles in North America</li>
</ul>
</li>
</ul>

Contracts

BorgWarner Wins High-Voltage Coolant Heater Contract With Global OEM; Terms Not Disclosed

Uniti Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNIT#NASDAQ">UNIT</a>) lowers FY2025 FFO guidance from $1.40-$1.47 to $1.32-$1.39 vs $1.40 analyst estimate. Affirms FY2025 sales outlook from $1.20 billion-$1.22 billion to $1.20 billion-$1.22 billion vs $2.61 billion estimate.

UNIT

Uniti Group Lowers FY2025 FFO Guidance from $1.40-$1.47 to $1.32-$1.39 vs $1.40 Est; Affirms FY2025 Sales Guidance of $1.20B-$1.22B vs $2.61B Est

BCDA

BioCardia Initiates Patient Enrollment At University Of Wisconsin At Madison For Ongoing CardiAMP HF II Pivotal Study

Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) reported quarterly losses of $(2.11) per share which beat the analyst consensus estimate of $(2.74) by 22.99 percent. This is a 62.19 percent increase over losses of $(5.58) per share from the same period last year. The company reported quarterly sales of $311.00 thousand which missed the analyst consensus estimate of $333.33 thousand by 6.70 percent. This is a 68.46 percent decrease over sales of $986.00 thousand the same period last year.

ALGS

Aligos Therapeutics Q1 EPS $(2.11) Beats $(2.74) Estimate, Revenue $311.00K Miss $333.33K Estimate

IPG Photonics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPGP#NASDAQ">IPGP</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.21 by 47.62 percent. This is a 38 percent decrease over earnings of $0.50 per share from the same period last year. The company reported quarterly sales of $227.79 million which beat the analyst consensus estimate of $227.10 million by 0.30 percent. This is a 9.61 percent decrease over sales of $252.01 million the same period last year.

IPG Photonics Q1 Adj. EPS $0.31 Beats $0.21 Estimate, Sales $227.79M Beat $227.10M Estimate

Apollo Funds To Acquire Hav Energy From HitecVision; Financial Terms Not Disclosed

CRIS

Curis Q1 EPS $(1.25) Misses $(0.87) Estimate, Sales $2.38M Miss $2.75M Estimate

Great Lakes Dredge &amp; Dock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLDD#NASDAQ">GLDD</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.26 by 88.46 percent. This is a 58.06 percent increase over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $242.87 million which beat the analyst consensus estimate of $206.70 million by 17.50 percent. This is a 22.25 percent increase over sales of $198.66 million the same period last year.

GLDD

Great Lakes Dredge & Dock Q1 GAAP EPS $0.49 Beats $0.26 Estimate, Sales $242.87M Beat $206.70M Estimate

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy  Designation For OPGx-LCA5 Gene Therapy Candidate

Uniti Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNIT#NASDAQ">UNIT</a>) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.34 by 2.94 percent. This is a 9.37 percent increase over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of $293.91 million which missed the analyst consensus estimate of $295.79 million by 0.63 percent. This is a 2.62 percent increase over sales of $286.42 million the same period last year.

Comments

Red Canyon Resources

Vendite allo scoperto

Red Canyon Resources (OTC:REDRF) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO